and delivers a new drug. ''Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease,'' the FDA said yesterday in a statement. The patch delivers a drug called rotigotine to treat the fatal and incurable brain disease.
Rotigotine is similar to other drugs used to treat Parkinson's -- it is a so-called dopamine agonist, which provides more dopamine, a message-carrying chemical, to the brain.
Parkinson's is caused when dopamine-producing cells are mistakenly destroyed in the brain. It is marked by worsening tremors and paralysis.
There is no cure and all treatments eventually stop working.
The Neupro patch is replaced every 24 hours and provides a continuous dose of the drug.
''The most common side effects for Neupro included skin reactions at the patch site, dizziness, nausea, vomiting, drowsiness and insomnia, most of which are typical of this class of drugs,'' the FDA said.
According to the Parkinson's Action Network, more than one million Americans have Parkinson's disease and 60,000 new cases are diagnosed each year.
-- (Reuters) -- 10FN37.XML
US committed to Iraq withdrawal, says Biden
Police, protesters clash ahead of G8 in Italy
Lady Liberty statue reopened to freedom tourists
New swine flu case takes India\'s tally to 129
Mango festival starts in Haryana
Revocation of AFSPA should be left to Centre: Ansari
President urges civil servants to have a development-centric approach
Serena turns tables on Venus for third Wimbledon title
